Biomimetic platforms, such as organs-on-a-chip, will provide unprecedented opportunities to accurately evaluate the safety and efficacy of nanomedicine formulations, leading to higher clinical trial success rates.
No takes yet. Share an insight, caveat, or question.
Jang et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: